Open company graph database — free web & API
Login

J-Pharma Inc.

ジェイファーマ株式会社J-Pharma Co.,Ltd.Alias
Ticker
—
Listed market
—
Country
Japan
Employees (consolidated)
18
Related companies
0
§01

Basic information

BASIC
Head office
8th Floor, VORT Hamamatsucho II, 1-10-11 Hamamatsucho, Minato-ku, Tokyo 105-0013, Japan
Chief executive
Masahiro Yoshitake
Capital
2,033,000,000  (20 100 million)
Employees (non-consolidated)
18 people
Employees (consolidated)
18 people
Start date
2005-12-26
End date
§02

Websites

1 DOMAINS
§03

Business

7
Pharmaceutical developmentCancer treatment drug developmentAutoimmune disease treatment drug developmentRare disease treatment drug developmentLAT1 inhibitor clinical trialsTransporter inhibitor creationDrug discovery platform development
§04

Related companies

0 COMPANIES

—

§05

Network

NETWORK
Drag to move · click to open
§06

History

35 EVENTS

Established J-Pharma Inc. as a company specializing in drug development targeting cell membrane transporters in Toranomon 1-chome, Minato-ku, Tokyo.Sources

Founded J-Pharma Inc. in Toranomon 1-chome, Minato-ku, Tokyo, as a company specializing in drug development targeting cell membrane transportersSources

Supported the development of a hyperphosphatemia treatment drug through the Pharmaceutical Infrastructure Research Institute's project for practical application of pharmaceuticals and medical devices.Sources

Relocated head office to 2-chome, Shinjuku, Tokyo.Sources

Supported the development of a gastric cancer therapy through NEDO's innovation commercialization support project.Sources

Supported the development of a novel molecular probe targeting cancer cell-specific membrane proteins through the Ministry of Education, Culture, Sports, Science and Technology's molecular imaging research program.Sources

Supported the research and development of a new phosphate adsorbent JPH101 and Phase 1 clinical trials through NEDO's innovation promotion project.Sources

Established Tajima CPA Office in 2010, providing management and funding support mainly for biotech ventures.Sources

Supported the development of a new anti-cancer therapy targeting the essential amino acid transporter LAT1 expressed in cancer cells, bridging basic and clinical research.Sources

Supported the clinical development of an innovative anti-cancer drug by inhibiting amino acid transporters through NEDO's venture commercialization support project.Sources

Relocated head office to Tsurumi-ku, Yokohama, Kanagawa.Sources

Supported the development of an in vitro diagnostic kit for triple-negative malignant breast cancer through Yokohama City special zone leading project grant.Sources

Supported the clinical trial of a new anti-cancer drug JPH203 to secure proof of concept (POC) through NEDO's venture commercialization support project.Sources

Supported the commercialization of an in vitro diagnostic for triple-negative breast cancer through Yokohama City special zone leading project grant.Sources

Initiated Phase 1 clinical trial of LAT1 inhibitor Namburanlat (development code: JPH203) in JapanSources

Completed Phase 1 clinical trial of Namburanlat in JapanSources

Initiated Phase 2 clinical trial of Namburanlat in JapanSources

Signed license and joint development agreement with Ohara Pharmaceutical Co., Ltd. regarding NamburanlatSources

Signed license and joint development agreement with Ohara Pharmaceutical Co., Ltd. regarding NamburanlatSources

Namburanlat designated as an orphan drug (rare disease drug) by the U.S. Food and Drug Administration (FDA)Sources

Namburanlat designated as an orphan drug (rare disease drug) by the U.S. Food and Drug Administration (FDA)Sources

Completed Phase 2 clinical trial of Namburanlat in JapanSources

Development of central nervous system-penetrant LAT1 inhibitor (development code: JPH034) for multiple sclerosis was adopted by the U.S. National Multiple Sclerosis Society (NMSS) Fast Forward commercialization research grant program and received fundingSources

Established J-Pharma USA to recruit personnel for drug development in the U.S. (liquidated in July 2025)Sources

JPH034 was adopted by the Japan Agency for Medical Research and Development (AMED) 'Drug Discovery Venture Ecosystem Enhancement Project'Sources

IND application for clinical trials of Namburanlat in cancer patients approved by the U.S. Food and Drug Administration (FDA)Sources

IND application for clinical trials of Namburanlat in cancer patients approved by the U.S. Food and Drug Administration (FDA)Sources

Received positive response from the U.S. FDA regarding CMC (Chemistry, Manufacturing, and Controls) of Namburanlat, confirming compliance with quality standards required for commercial manufacturing in the U.S.Sources

Relocated head office to Hamamatsucho, Minato-ku, TokyoSources

Started global Phase 3 clinical trial of Namburanlat (targeting second-line therapy for biliary tract cancer)Sources

IND safety review by the U.S. FDA completed for the start of Phase 1 trial of JPH034 in the U.S.Sources

Initiated Phase 1 clinical trial of JPH034Sources

Listed on the Tokyo Stock Exchange Growth MarketSources

The Phase 1 clinical trial of "JPH034" is registered on ClinicalTrials.govSources

The physician-led clinical trial for biliary tract cancer of Nanbrant Rato is registered on jRCTSources

§07

News

0 ARTICLES

There is no news.

§08

Public records

GOV
National Tax Agency basic information6011101043476
Source: National Tax Agency Corporate Number Publication Site, basic three itemsSources
Trade name
ジェイファーマ株式会社
Trade name (kana)
ジェイファーマ
Name in English
Corporation type
301
Address
〒105-0013 東京都港区浜松町1丁目10番11号
Postal code
1050013
Prefecture code
13
City code
103
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2025-07-09
Change date
2025-07-04
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
2099647
METI gBizINFO6011101043476
Source: gBizINFO (Ministry of Economy, Trade and Industry)Sources
Corporate number
6011101043476
Trade name
ジェイファーマ株式会社
Trade name (kana)
ジェイファーマ
Trade name (alphabet)
Registry closure date
Reason for registry closure
Registered address
東京都港区浜松町1丁目10番11号
Postal code
1050013
Prefecture
東京都
Prefecture code
13
City or district
港区
City code
103
Street address
浜松町1丁目10番11号
Organisation type
301
Processing type
12
Correction type
0
Status
Representative
代表取締役社長  吉武 益広
Capital
2032697000
Employees
16
Employees (male)
Employees (female)
Business summary
Website URL
Year founded
Business category
Date established
Unified government qualification - grade
Unified government qualification - business items
Update date
2025-07-09
Key information
6011101043476
§09

Sources & updates

SOURCES
↑